Title

Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation

Authors

Authors

Y. C. Chung; S. R. Kim; J. Y. Park; E. S. Chung; K. W. Park; S. Y. Won; E. Bok; M. Jin; E. S. Park; S. H. Yoon; H. W. Ko; Y. S. Kim;B. K. Jin

Comments

Authors: contact us about adding a copy of your work at STARS@ucf.edu

Abbreviated Journal Title

Neuropharmacology

Keywords

Parkinson's disease; Fluoxetine; Microglial activation; Oxidative; stress; Neuroinflammation; NITRIC-OXIDE SYNTHASE; PARKINSONS-DISEASE; NADPH OXIDASE; IN-VIVO; SUBSTANTIA-NIGRA; OXIDATIVE STRESS; MOUSE MODEL; CELL-DEATH; TNF-ALPHA; MICE; Neurosciences; Pharmacology & Pharmacy

Abstract

Parkinson's disease (PD) is characterized by degeneration of nigrostriatal dopaminergic (DA) neurons. Mice treated with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) exhibit microglial activation-induced oxidative stress and inflammation, and nigrostriatal DA neuronal damage, and thus serve as an experimental model of PD. Here, we report that fluoxetine, one of the most commonly prescribed antidepressants, prevents MPTP-induced degeneration of nigrostriatal DA neurons and increases striatal dopamine levels with the partial motor recovery. This was accompanied by inhibiting transient expression of proinflammatory cytokines and inducible nitric oxide synthase; and attenuating microglial NADPH oxidase activation, reactive oxygen species/reactive nitrogen species production, and consequent oxidative damage. Interestingly, fluoxetine was found to protect DA neuronal damage from 1-methy1-4-phenyl-pyridinium (MPP(+)) neurotoxicity in co-cultures of mesencephalic neurons and microglia but not in neuron-enriched mesencephalic cultures devoid of microglia. The present in vivo and in vitro findings show that fluoxetine may possess anti-inflammatory properties and inhibit glial activation-mediated oxidative stress. Therefore, we carefully propose that neuroprotection of fluoxetine might be associated with its anti-inflammatory properties and could be employed as novel therapeutic agents for PD and other disorders associated with neuroinflammation and microglia-derived oxidative damage. (C) 2011 Elsevier Ltd. All rights reserved.

Journal Title

Neuropharmacology

Volume

60

Issue/Number

6

Publication Date

1-1-2011

Document Type

Article

Language

English

First Page

963

Last Page

974

WOS Identifier

WOS:000289133200017

ISSN

0028-3908

Share

COinS